Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biochemical Brain Changes with Escitalopram in MDD
NCT00183677Phase 4Completed
- Sponsor
- Massachusetts General Hospital
- Start
- Jul 2003
- Primary completion
- Jun 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of escitalopram in major depressive disorder (MDD), sponsored by Massachusetts General Hospital. Primary endpoint: Responder and Remission Status Based on the Depression Rating Scale Score at 12 weeks. Started Jul 2003; status: completed.
02
Drugs
escitalopram
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on NCT00183677.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00183677.